DK1572214T3 - Morpholinderivater til anvendelse som dopaminagonister ved behandling af bl.a. seksuel dysfunktion - Google Patents

Morpholinderivater til anvendelse som dopaminagonister ved behandling af bl.a. seksuel dysfunktion

Info

Publication number: DK1572214T3
Authority: DK; Denmark
Prior art keywords: treatment; sexual dysfunction; dopamine agonists; morpholine derivatives; morpholine
Prior art date: 2002-12-10

Application number

DK03812639.7T

Other languages

English (en)

Inventor

Andrew Douglas Baxter

Andrew Simon Cook

David Hepworth

Stephen Kwok-Fung Wong

Charlotte Moira Norfor Allerton

Original Assignee

Pfizer Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-10

Filing date

2003-12-02

Publication date

2010-06-07

2002-12-10 Priority claimed from GB0228787A external-priority patent/GB0228787D0/en

2003-04-11 Priority claimed from GB0308460A external-priority patent/GB0308460D0/en

2003-06-12 Priority claimed from GB0313606A external-priority patent/GB0313606D0/en

2003-12-02 Application filed by Pfizer Ltd filed Critical Pfizer Ltd

2010-06-07 Application granted granted Critical

2010-06-07 Publication of DK1572214T3 publication Critical patent/DK1572214T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Gynecology & Obstetrics (AREA)
Hematology (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Diabetes (AREA)
Addiction (AREA)
Dermatology (AREA)
Nutrition Science (AREA)
Pregnancy & Childbirth (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)

DK03812639.7T 2002-12-10 2003-12-02 Morpholinderivater til anvendelse som dopaminagonister ved behandling af bl.a. seksuel dysfunktion DK1572214T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0228787A GB0228787D0 (en)	2002-12-10	2002-12-10	Morpholine dopamine agonists
GB0308460A GB0308460D0 (en)	2003-04-11	2003-04-11	Morpholine dopamine agonists
GB0313606A GB0313606D0 (en)	2003-06-12	2003-06-12	Morpholine dopamine agonists
PCT/IB2003/005683 WO2004052372A1 (en)	2002-12-10	2003-12-02	Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction

Publications (1)

Publication Number	Publication Date
DK1572214T3 true DK1572214T3 (da)	2010-06-07

Family

ID=32512061

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03812639.7T DK1572214T3 (da)	2002-12-10	2003-12-02	Morpholinderivater til anvendelse som dopaminagonister ved behandling af bl.a. seksuel dysfunktion

Country Status (36)

Country	Link
EP (1)	EP1572214B1 (da)
JP (3)	JP3889775B2 (da)
KR (1)	KR100796102B1 (da)
AP (1)	AP2005003325A0 (da)
AR (1)	AR042339A1 (da)
AT (1)	ATE460938T1 (da)
AU (1)	AU2003302878B2 (da)
CA (1)	CA2508262C (da)
CO (1)	CO5700781A2 (da)
CR (1)	CR7869A (da)
CY (1)	CY1110130T1 (da)
DE (1)	DE60331769D1 (da)
DK (1)	DK1572214T3 (da)
EA (1)	EA009589B1 (da)
EC (1)	ECSP055850A (da)
ES (1)	ES2339767T3 (da)
GE (1)	GEP20074272B (da)
HN (1)	HN2003000401A (da)
HR (1)	HRP20050523A2 (da)
IS (1)	IS7843A (da)
MA (1)	MA27605A1 (da)
MX (1)	MXPA05006151A (da)
MY (1)	MY144338A (da)
NL (1)	NL1024983C2 (da)
NO (1)	NO330143B1 (da)
NZ (1)	NZ540505A (da)
OA (1)	OA13014A (da)
PA (1)	PA8591601A1 (da)
PE (1)	PE20040906A1 (da)
PL (1)	PL377480A1 (da)
PT (1)	PT1572214E (da)
RS (1)	RS51442B (da)
SI (1)	SI1572214T1 (da)
TW (1)	TW200423944A (da)
UY (1)	UY28117A1 (da)
WO (1)	WO2004052372A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE404560T1 (de) *	2004-05-26	2008-08-15	Pfizer	Indazol- und indolonderivative und deren verwendung als pharmazeutika
JP4198183B2 (ja) *	2004-05-27	2008-12-17	ファイザー・インク	選択的ドーパミンｄ３アゴニストとしてのアミノピリジン誘導体
GB0502509D0 (en)	2005-02-07	2005-03-16	Pfizer Ltd	Novel salt form of a dopamine agonist
TW200740779A (en)	2005-07-22	2007-11-01	Mitsubishi Pharma Corp	Intermediate compound for synthesizing pharmaceutical agent and production method thereof
GB0700786D0 (en) *	2007-01-15	2007-02-21	Pfizer Ltd	Morpholine dopamine agonists for the treatment of pain
AU2011255456B2 (en)	2010-05-21	2017-01-19	Dignity Health Doing Business As St. Joseph's Hospital And Medical Center And Barrow Neurological Institute	1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
EP2571858B1 (en) *	2010-05-21	2018-06-20	Research Triangle Institute	Phenylmorpholines and analogues thereof
RU2677328C1 (ru) *	2013-12-11	2019-01-16	Ф. Хоффманн-Ля Рош Аг	Способ получения хиральных 2-арилморфолинов
GB2543296A (en)	2015-10-13	2017-04-19	Indivior Uk Ltd	Dopamine D3 receptor antagonists having a morpholine moiety
EP3725768A1 (en) *	2019-04-17	2020-10-21	Newron Pharmaceuticals S.p.A.	Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives
CN118684636B (zh) *	2024-05-31	2025-03-11	上海优合贝德医药科技有限公司	一种4-吗啉-1-苯基巯基-2-丁酮的合成工艺

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB851311A (en) *	1958-04-02	1960-10-12	Geigy Ag J R	Morpholine compounds and their production
GB9108629D0 (en) *	1991-04-23	1991-06-12	Wellcome Found	Heterocyclic pharmaceutical compounds,preparation and use
GB0130219D0 (en) *	2001-12-18	2002-02-06	Pfizer Ltd	Compounds for the treatment of sexual dysfunction

2003
- 2003-12-02 EA EA200500801A patent/EA009589B1/ru not_active IP Right Cessation
- 2003-12-02 CA CA002508262A patent/CA2508262C/en not_active Expired - Fee Related
- 2003-12-02 MX MXPA05006151A patent/MXPA05006151A/es active IP Right Grant
- 2003-12-02 PT PT03812639T patent/PT1572214E/pt unknown
- 2003-12-02 DE DE60331769T patent/DE60331769D1/de not_active Expired - Lifetime
- 2003-12-02 DK DK03812639.7T patent/DK1572214T3/da active
- 2003-12-02 SI SI200331801T patent/SI1572214T1/sl unknown
- 2003-12-02 AP AP2005003325A patent/AP2005003325A0/xx unknown
- 2003-12-02 NZ NZ540505A patent/NZ540505A/en not_active IP Right Cessation
- 2003-12-02 EP EP03812639A patent/EP1572214B1/en not_active Expired - Lifetime
- 2003-12-02 RS YUP-2005/0445A patent/RS51442B/en unknown
- 2003-12-02 PL PL377480A patent/PL377480A1/pl not_active Application Discontinuation
- 2003-12-02 KR KR1020057010474A patent/KR100796102B1/ko not_active Expired - Fee Related
- 2003-12-02 HR HR20050523A patent/HRP20050523A2/hr not_active Application Discontinuation
- 2003-12-02 WO PCT/IB2003/005683 patent/WO2004052372A1/en active Application Filing
- 2003-12-02 GE GEAP20038838A patent/GEP20074272B/en unknown
- 2003-12-02 ES ES03812639T patent/ES2339767T3/es not_active Expired - Lifetime
- 2003-12-02 AT AT03812639T patent/ATE460938T1/de active
- 2003-12-02 AU AU2003302878A patent/AU2003302878B2/en not_active Ceased
- 2003-12-02 OA OA1200500171A patent/OA13014A/en unknown
- 2003-12-02 JP JP2005502342A patent/JP3889775B2/ja not_active Expired - Fee Related
- 2003-12-05 PE PE2003001234A patent/PE20040906A1/es not_active Application Discontinuation
- 2003-12-08 MY MYPI20034690A patent/MY144338A/en unknown
- 2003-12-09 HN HN2003000401A patent/HN2003000401A/es unknown
- 2003-12-09 AR ARP030104524A patent/AR042339A1/es unknown
- 2003-12-09 TW TW092134694A patent/TW200423944A/zh unknown
- 2003-12-10 PA PA20038591601A patent/PA8591601A1/es unknown
- 2003-12-10 NL NL1024981A patent/NL1024983C2/nl not_active IP Right Cessation
- 2003-12-10 UY UY28117A patent/UY28117A1/es not_active Application Discontinuation
2005
- 2005-05-12 IS IS7843A patent/IS7843A/is unknown
- 2005-05-26 NO NO20052557A patent/NO330143B1/no not_active IP Right Cessation
- 2005-06-10 EC EC2005005850A patent/ECSP055850A/es unknown
- 2005-06-10 CO CO05056566A patent/CO5700781A2/es not_active Application Discontinuation
- 2005-06-10 CR CR7869A patent/CR7869A/es unknown
- 2005-06-10 MA MA28324A patent/MA27605A1/fr unknown
2006
- 2006-06-06 JP JP2006157609A patent/JP3920908B2/ja not_active Expired - Fee Related
- 2006-12-27 JP JP2006352505A patent/JP4624341B2/ja not_active Expired - Fee Related
2010
- 2010-04-26 CY CY20101100367T patent/CY1110130T1/el unknown

Also Published As

Publication number	Publication date
JP3889775B2 (ja)	2007-03-07
TW200423944A (en)	2004-11-16
DE60331769D1 (de)	2010-04-29
MA27605A1 (fr)	2005-11-01
PE20040906A1 (es)	2005-01-24
NL1024983A1 (nl)	2004-06-11
AP2005003325A0 (en)	2005-06-30
HRP20050523A2 (en)	2005-08-31
JP2006232857A (ja)	2006-09-07
NZ540505A (en)	2007-02-23
NO20052557D0 (no)	2005-05-26
WO2004052372A1 (en)	2004-06-24
NL1024983C2 (nl)	2005-02-01
EP1572214A1 (en)	2005-09-14
PL377480A1 (pl)	2006-02-06
EA200500801A1 (ru)	2005-12-29
ATE460938T1 (de)	2010-04-15
SI1572214T1 (sl)	2010-07-30
AR042339A1 (es)	2005-06-15
AU2003302878A1 (en)	2004-06-30
CO5700781A2 (es)	2006-11-30
EA009589B1 (ru)	2008-02-28
PT1572214E (pt)	2010-05-06
CA2508262A1 (en)	2004-06-24
ECSP055850A (es)	2005-09-20
AU2003302878B2 (en)	2009-04-23
KR100796102B1 (ko)	2008-01-21
CR7869A (es)	2005-07-08
MXPA05006151A (es)	2005-08-26
KR20050094813A (ko)	2005-09-28
JP2007084575A (ja)	2007-04-05
HN2003000401A (es)	2004-11-23
OA13014A (en)	2006-11-10
CY1110130T1 (el)	2015-01-14
RS20050445A (en)	2007-04-10
RS51442B (en)	2011-04-30
NO20052557L (no)	2005-09-06
PA8591601A1 (es)	2004-12-16
IS7843A (is)	2005-05-12
NO330143B1 (no)	2011-02-21
CA2508262C (en)	2009-12-01
JP4624341B2 (ja)	2011-02-02
UY28117A1 (es)	2004-07-30
JP3920908B2 (ja)	2007-05-30
MY144338A (en)	2011-08-29
EP1572214B1 (en)	2010-03-17
ES2339767T3 (es)	2010-05-25
HK1081850A1 (zh)	2006-05-26
GEP20074272B (en)	2007-12-25
JP2006511599A (ja)	2006-04-06

Publication	Publication Date	Title
NO20053215D0 (no)	2005-06-30	Pyrazolderivater med anvendelse som COX-1-inhibitorer.
NO20053775D0 (no)	2005-08-08	Diazepinoindol derivater som kinaseinhibitorer.
DK1789041T3 (da)	2008-09-08	Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
NO20044654L (no)	2004-10-28	Piperidinoylpiperidiner som 5-HTIF-agonister
DK1492785T3 (da)	2009-03-02	2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
CY2015036I1 (el)	2016-06-22	Νεα παραγωγα οξαζολιδινονης
DK2270008T3 (da)	2013-01-14	8-Heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-oner som PI-3-kinaseinhibitorer
DE602004012154D1 (de)	2008-04-10	Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren
NO20050665L (no)	2005-04-18	Pyrrolidonderivater som MAOE inhibitoere
DK1670458T3 (da)	2007-04-23	1-Amino-2-oxy-substituerede tetrahydronaphthalenderivater, fremgangsmåder til fremstilling deraf og deres anvendelse som antiphlogistika
DK2263674T3 (da)	2014-10-27	10,10-Dialkyl-prostansyrederivater som midler til sænkning af intraokulært tryk
DK1572214T3 (da)	2010-06-07	Morpholinderivater til anvendelse som dopaminagonister ved behandling af bl.a. seksuel dysfunktion
DK1879580T3 (da)	2009-05-18	4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolinderivater som lægemidler til behandling af infertilitet
DK1740569T3 (da)	2008-06-02	Imidazol-derivater som TAFla-inhibitorer
DK1763517T3 (da)	2011-06-06	Pyrimidinderivater som 11beta-HSD1-inhibitorer
DK1881830T3 (da)	2009-01-26	4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater til behandling af infertilitet
ATE496049T1 (de)	2011-02-15	Als monoamin wiederaufnahmehemmer geeignete 8- azabicycloä3.2.1üoctanderivate
NO20030464L (no)	2004-08-02	Anordning ved skrueturbin.
DK1511718T3 (da)	2009-06-22	N-acylaminobenzenderivater som selektive monoaminoxidase B-inhibitorer
DK1711177T3 (da)	2008-09-29	1H-thieno-2,3-c-pyrazolderivater, der er egnede som kinase-I-inhibitorer
DK1879581T3 (da)	2008-12-15	4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater som lægemidler til behandling af infertilitet
DK1801108T3 (da)	2013-02-18	Morpholinforbindelser til behandling af inflammationer.
ITRM20030153A1 (it)	2004-10-04	Formulazione idrosolubile contenente ubichinone per uso oftalmico.
DK1828166T3 (da)	2009-10-05	Hydantoinderivater, der kan anvendes som metalloproteinase-inhibitorer
DK1749001T3 (da)	2010-06-28	3-piperidinylisochroman-5-ol som dopaminagonister